Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses
Open Access
- 20 September 2013
- journal article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 20 (10), 590-598
- https://doi.org/10.1038/cgt.2013.60
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude miceBreast Cancer Research and Treatment, 2013
- Trial watch Dendritic cell-based interventions for cancer therapyOncoImmunology, 2012
- Recent Developments in Cancer VaccinesThe Journal of Immunology, 2011
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunityBlood, 2006
- Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor ProgressionThe Journal of Experimental Medicine, 2004
- Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachmentCell, 1993
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987